Lizzul Paul F. 4
4 · ANAPTYSBIO, INC · Filed Jan 6, 2026
Insider Transaction Report
Form 4
ANAPTYSBIO, INCANAB
Lizzul Paul F.
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2026-01-03+10,555→ 37,522 total - Sale
Common Stock
2026-01-05$43.26/sh−4,219$182,514→ 33,303 total - Exercise/Conversion
Restricted Stock Unit
2026-01-03−10,555→ 21,110 total→ Common Stock (10,555 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.